The Effect of Proton Pump Inhibitor and Polaprezinc Combination Therapy for Healing of Endoscopic Submucosal Dissection-induced Ulcer
Status
Conditions
Treatments
Details and patient eligibility
About
Endoscopic submucosal dissection (ESD) is an advanced technique that enables en bloc resection of superficial tumors in the gastrointestinal tract. ESD, however, is a time-consuming procedure that requires a high level of endoscopic skill to achieve a desirable oncologic outcome. Several procedure-related complications may occur after ESD. Especially, iatrogenic ulcer bleeding after ESD can be a concern for both endoscopists and patients. In order to reduce the bleeding rate, proton pump inhibitors (PPIs) are administered after ESD. In addition, ulcer protective agents such as rebamipide can be added to PPIs for accelerating ulcer healing. We aimed to evaluate the efficacy of polaprezinc for healing of iatrogenic ulcer.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Age, between 19 and 79
- Patients with gastric adenoma or early gastric cancer
- Patients with ECOG-PS 0 or 1
- Patients with adequate renal function
- Patients with adequate hepatic function
- Patients with adequate bone marrow function
Exclusion criteria
- Patients who has taken the medications for ulcer including PPIs, H2 blockers, and mucosal protective agents within 3 months prior to the ESD.
- Patients who has taken steroid or NSAIDswithin 3 months prior to the ESD.
- Patients who has undergone gastrostomy
- Patients with allergy for pantoprazole, polaprezinc, or rebamipide.
- Pregnant or breast feeding.
Trial design
Primary purpose
Allocation
Interventional model
Masking
153 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal